Northwire Canada EditionSunday, October 18, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4181.10 +0.3% SILVER 57.30 +0.3% COPPER 6.57 +0.3% OIL 99.02 +1.1% PALLADIUM 1118.60 −0.9% GBU 0.095 +0.0% ATY 0.225 +4.7% GRDM 0.215 +0.0% PPM 0.300 +0.0% GZD 0.040 −11.1% CAN 0.060 +0.0% BGF 0.025 +0.0% MSV 0.570 +0.0% CCMM 0.485 +0.0% MON 0.385 −6.1% OMI 0.245 −2.0% BUFF 0.800 +2.6% FEO 0.630 −3.1% LIB 0.710 −1.4% NPR 0.620 +0.0% QZM 0.380 +0.0% GOLD 4181.10 +0.3% SILVER 57.30 +0.3% COPPER 6.57 +0.3% OIL 99.02 +1.1% PALLADIUM 1118.60 −0.9% GBU 0.095 +0.0% ATY 0.225 +4.7% GRDM 0.215 +0.0% PPM 0.300 +0.0% GZD 0.040 −11.1% CAN 0.060 +0.0% BGF 0.025 +0.0% MSV 0.570 +0.0% CCMM 0.485 +0.0% MON 0.385 −6.1% OMI 0.245 −2.0% BUFF 0.800 +2.6% FEO 0.630 −3.1% LIB 0.710 −1.4% NPR 0.620 +0.0% QZM 0.380 +0.0%

Healthcare

Page 110
  1. Oct 31, 2025 · 18:00 · ONCO

    Onco-Innovations Provides Shareholder Update Following Cboe Canada Investor Spotlight

    Onco-Innovations Provides Shareholder Update Following Cboe Canada Investor Spotlight

    01
  2. Oct 31, 2025 · 17:15 · GUD

    Knight Announces Closing of US$100 Million Revolving Credit Facility

    Knight Announces Closing of US$100 Million Revolving Credit Facility

    02
  3. Oct 31, 2025 · 17:13 · WELL

    Well Health's Wellstar arranges $62M Series B financing

    Well Health's Wellstar arranges $62M Series B financing

    03
  4. Oct 31, 2025 · 16:26 · PHRX

    Pharmadrug arranges $445,686 debt restructuring

    Pharmadrug arranges $445,686 debt restructuring

    04
  5. Oct 31, 2025 · 15:52 · PTEC

    Principal signs R&D deal with University of Oxford

    Principal signs R&D deal with University of Oxford

    05
  6. Oct 31, 2025 · 08:15 · WELL

    WELL Subsidiary WELLSTAR Technologies Announces $62M Financing to Support Its Pre-Spinout Growth Strategy

    WELL Subsidiary WELLSTAR Technologies Announces $62M Financing to Support Its Pre-Spinout Growth Strategy

    06
  7. Oct 31, 2025 · 07:30 · PTEC

    PRINCIPAL TECHNOLOGIES ENTERS R&D AGREEMENT WITH OXFORD AND DIVESTS OF MAJORITY OWNERSHIP OF E&E CRO CONSULTING

    PRINCIPAL TECHNOLOGIES ENTERS R&D AGREEMENT WITH OXFORD AND DIVESTS OF MAJORITY OWNERSHIP OF E&E CRO CONSULTING

    07
  8. Oct 31, 2025 · 02:36 · 4565

    Nxera Pharma Receives a Manufacturing Approval Partial Amendment Regarding the Addition of a Manufacturing Site in Asia for QUVIVIQ(TM) 25 and 50 mg

    Nxera Pharma Receives a Manufacturing Approval Partial Amendment Regarding the Addition of a Manufacturing Site in Asia for QUVIVIQ(TM) 25 and 50 mg

    08
  9. Oct 31, 2025 · 02:34 · 4565

    Nxera Pharma Operational Highlights and Consolidated Results for the Third Quarter and First Nine Months of 2025

    Nxera Pharma Operational Highlights and Consolidated Results for the Third Quarter and First Nine Months of 2025

    09
  10. Oct 30, 2025 · 20:23 · HEM

    Hemostemix talks work in Florida

    Hemostemix talks work in Florida

    10
  11. Oct 30, 2025 · 19:00 · 4875

    MediciNova Compounds Demonstrate Novel Therapeutic Approach for Atherosclerosis in Peer-Reviewed Publication

    MediciNova Compounds Demonstrate Novel Therapeutic Approach for Atherosclerosis in Peer-Reviewed Publication

    11
  12. Oct 30, 2025 · 18:29 · PHRX

    Pharmadrug firms up deal to acquire 40% of Canurta

    Pharmadrug firms up deal to acquire 40% of Canurta

    12
  13. Oct 30, 2025 · 17:45 · GLAS

    Glass House Brands to release Q3 results Nov. 12

    Glass House Brands to release Q3 results Nov. 12

    13
  14. Oct 30, 2025 · 17:15 · GUD

    Knight Therapeutics Announces Launch of JORNAY PM(TM) in Canada

    Knight Therapeutics Announces Launch of JORNAY PM(TM) in Canada

    14
← Newer Older →